A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma, Clear Cell
  • Ovarian Neoplasms
  • Ovary

abstract

  • The antitumor activity noted with the use of a dose of 40 mg of apitolisib daily was limited by tolerability, especially in diabetic patients. Patients with PI3K pathway mutations may have derived enhanced benefit from apitolisib. Cancer 2016. © 2016 American Cancer Society.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5600677

Digital Object Identifier (DOI)

  • 10.1002/cncr.30286

PubMed ID

  • 27603005

Additional Document Info